Abstract
Abnormalities in microRNA expression in tumor cells are widely used as a basis to develop novel therapeutic and diagnostic approaches in oncology. The former mostly aims to target oncogenic microRNAs or to restore expression of microRNAs with tumor suppressor properties in cancer cells. However recently another way of using specific microRNA loss in tumor cells has been suggested. The strategy relies on frequently lost in cancer cells but abundant in cell of normal tissues specific microRNAs, and aims to control unwanted expression of a gene essential for therapeutic action, either therapeutic transgene or essential for viral replication gene in oncolytic viruses, thus minimizing damage to normal tissues and improving safety of cancer gene therapy. Here, history of development and basic principles of the approach as well as current progress in the field are overviewed, with emphasis on benefits brought by the microRNA-based control of specificity for cancer gene therapy and emerging possibility of personification of treatment.
Current Cancer Therapy Reviews
Title:MicroRNAs in Cancer Gene Therapy: Another Look
Volume: 10 Issue: 3
Author(s): Igor V. Korobko
Affiliation:
Keywords: Cancer gene therapy; microRNA; tumor specificity.
Abstract: Abnormalities in microRNA expression in tumor cells are widely used as a basis to develop novel therapeutic and diagnostic approaches in oncology. The former mostly aims to target oncogenic microRNAs or to restore expression of microRNAs with tumor suppressor properties in cancer cells. However recently another way of using specific microRNA loss in tumor cells has been suggested. The strategy relies on frequently lost in cancer cells but abundant in cell of normal tissues specific microRNAs, and aims to control unwanted expression of a gene essential for therapeutic action, either therapeutic transgene or essential for viral replication gene in oncolytic viruses, thus minimizing damage to normal tissues and improving safety of cancer gene therapy. Here, history of development and basic principles of the approach as well as current progress in the field are overviewed, with emphasis on benefits brought by the microRNA-based control of specificity for cancer gene therapy and emerging possibility of personification of treatment.
Export Options
About this article
Cite this article as:
V. Korobko Igor, MicroRNAs in Cancer Gene Therapy: Another Look, Current Cancer Therapy Reviews 2014; 10 (3) . https://dx.doi.org/10.2174/157339471003150212111836
DOI https://dx.doi.org/10.2174/157339471003150212111836 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Fluorescence Detection of MMP-9. I. MMP-9 Selectively Cleaves Lys-Gly-Pro-Arg-Ser-Leu-Ser-Gly-Lys Peptide
Current Pharmaceutical Biotechnology Targeting MDM2-p53 Interaction for Cancer Therapy: Are We There Yet?
Current Medicinal Chemistry RNA Silencing: Recent Developments on miRNAs
Recent Patents on DNA & Gene Sequences Paclitaxel Resistance: Molecular Mechanisms and Pharmacologic Manipulation
Current Cancer Drug Targets Clinical Experiment of Mutant Herpes Simplex Virus HF10 Therapy for Cancer
Current Cancer Drug Targets Vasoactive Intestinal Peptide Receptors: A Molecular Target in Breast and Lung Cancer
Current Pharmaceutical Design Small Molecular Inhibitors of p-STAT3: Novel Agents for Treatment of Primary and Metastatic CNS Cancers
Recent Patents on CNS Drug Discovery (Discontinued) Tyrosine Kinase Receptor Transactivation Associated to G Protein-Coupled Receptors
Current Drug Targets Herpes Simplex Virus Vectors for Gene Delivery to a Variety of Different Cell Types
Current Gene Therapy Transition Metal-Based Prodrugs for Anticancer Drug Delivery
Current Medicinal Chemistry Efficacy of Therapy with c-Met/HGF Inhibitors in Solid Tumors: A Systematic Review Based on 24 Clinical Trials
Clinical Cancer Drugs Molecular Mechanisms of Anti-cancer Action of Garlic Compounds in Neuroblastoma
Anti-Cancer Agents in Medicinal Chemistry Recent Developments on 1,2,4-Triazole Nucleus in Anticancer Compounds: A Review
Anti-Cancer Agents in Medicinal Chemistry Hibiscus Sabdariffa Linnaeus (Malvaceae), Curcumin and Resveratrol as Alternative Medicinal Agents Against Metabolic Syndrome
Cardiovascular & Hematological Agents in Medicinal Chemistry Organic Nanotheranostics for Photoacoustic Imaging-Guided Phototherapy
Current Medicinal Chemistry Antimicrobial, In Vitro and In Vivo Antineoplastic Activities, Mechanism of Action, Structural and Thermal Properties of a Small-Novel Pharmaceutical Organometallic Chelate
Mini-Reviews in Medicinal Chemistry Mechanisms of Allostery and Membrane Attachment in Ras GTPases: Implications for Anti-Cancer Drug Discovery
Current Medicinal Chemistry Src Inhibitors and Angiogenesis
Current Pharmaceutical Design Advances in Clinical Study of Curcumin
Current Pharmaceutical Design Treating Benign Prostatic Hyperplasia with Botulinum Neurotoxin
Current Medicinal Chemistry